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BACKGROUND
Among patients with aortic stenosis who are at intermediate or high risk for death 
with surgery, major outcomes are similar with transcatheter aortic-valve replacement 
(TAVR) and surgical aortic-valve replacement. There is insufficient evidence regard-
ing the comparison of the two procedures in patients who are at low risk.
METHODS
We randomly assigned patients with severe aortic stenosis and low surgical risk to 
undergo either TAVR with transfemoral placement of a balloon-expandable valve 
or surgery. The primary end point was a composite of death, stroke, or rehospitaliza-
tion at 1 year. Both noninferiority testing (with a prespecified margin of 6 percent-
age points) and superiority testing were performed in the as-treated population.
RESULTS
At 71 centers, 1000 patients underwent randomization. The mean age of the patients 
was 73 years, and the mean Society of Thoracic Surgeons risk score was 1.9% (with 
scores ranging from 0 to 100% and higher scores indicating a greater risk of death 
within 30 days after the procedure). The Kaplan–Meier estimate of the rate of the 
primary composite end point at 1 year was significantly lower in the TAVR group 
than in the surgery group (8.5% vs. 15.1%; absolute difference, −6.6 percentage 
points; 95% confidence interval [CI], −10.8 to −2.5; P<0.001 for noninferiority; 
hazard ratio, 0.54; 95% CI, 0.37 to 0.79; P = 0.001 for superiority). At 30 days, TAVR 
resulted in a lower rate of stroke than surgery (P = 0.02) and in lower rates of death 
or stroke (P = 0.01) and new-onset atrial fibrillation (P<0.001). TAVR also resulted 
in a shorter index hospitalization than surgery (P<0.001) and in a lower risk of a 
poor treatment outcome (death or a low Kansas City Cardiomyopathy Questionnaire 
score) at 30 days (P<0.001). There were no significant between-group differences 
in major vascular complications, new permanent pacemaker insertions, or moderate 
or severe paravalvular regurgitation.
CONCLUSIONS
Among patients with severe aortic stenosis who were at low surgical risk, the rate of 
the composite of death, stroke, or rehospitalization at 1 year was significantly 
lower with TAVR than with surgery. (Funded by Edwards Lifesciences; PARTNER 3 
ClinicalTrials.gov number, NCT02675114.)
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The role of transcatheter aortic-valve replacement (TAVR) in the treatment of patients with severe, symptomatic aortic 
stenosis has evolved on the basis of evidence from 
clinical trials.1-11 Previous randomized trials of 
TAVR with both balloon-expandable valves1-7 and 
self-expanding valves8-11 showed that, in patients 
who were at intermediate or high risk for death 
with surgery, TAVR was either superior or nonin-
ferior to standard therapies, including surgical 
aortic-valve replacement; these results led to an 
expansion of guideline recommendations for 
TAVR.12,13 Moreover, technological enhancements 
and procedural simplification have contributed 
to increased use of TAVR, such that more patients 
now undergo TAVR than isolated surgery for aor-
tic-valve replacement in the United States.14 How-
ever, most patients with severe aortic stenosis are 
at low surgical risk,15 and there is insufficient 
evidence regarding the comparison of TAVR with 
surgery in such patients.16,17 We report the find-
ings of the Placement of Aortic Transcatheter 
Valves (PARTNER) 3 trial, in which TAVR was 
compared with surgery in low-risk patients.
Me thods
Trial Design and Oversight
The PARTNER 3 trial was a multicenter, ran-
domized trial in which TAVR with transfemoral 
placement of a third-generation balloon-expand-
able valve was compared with standard surgical 
aortic-valve replacement in patients with severe 
aortic stenosis and a low risk of death with sur-
gery. A list of participating sites and investigators 
is provided in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
The trial protocol, available at NEJM.org, was de-
signed by the trial sponsor (Edwards Lifesciences) 
and the steering committee, with guidance from 
the Food and Drug Administration. The protocol 
was approved by the institutional review board 
at each site. The sponsor funded all trial-related 
activities and participated in site selection, data 
collection and monitoring, and statistical analy-
sis. The principal investigators (the first two au-
thors) and steering committee monitored all as-
pects of trial conduct. The principal investigators 
had unrestricted access to the data, prepared all 
drafts of the manuscript, and vouch for the com-
pleteness and accuracy of the data and analyses 
and the fidelity of the trial to the protocol. De-
tails regarding the trial design and administrative 
data are provided in Sections A and B and Figure 
S1 in the Supplementary Appendix.
Patients
Patients were eligible for inclusion in the trial if 
they had severe calcific aortic stenosis and were 
considered to be at low surgical risk according 
to the results of clinical and anatomical assess-
ment, including a Society of Thoracic Surgeons 
Predicted Risk of Mortality (STS-PROM) score of 
less than 4% (with scores ranging from 0 to 100% 
and higher scores indicating a greater risk of death 
within 30 days after the procedure) and agreement 
by the site heart team and the trial case review 
committee. Patients had to be eligible for TAVR 
with transfemoral placement of the balloon-
expandable SAPIEN 3 system (Edwards Life-
sciences). Patients with clinical frailty (as deter-
mined by the heart team), bicuspid aortic valves, 
or other anatomical features that increased the 
risk of complications associated with either TAVR 
or surgery were excluded. Details regarding inclu-
sion and exclusion criteria are provided in Section 
C in the Supplementary Appendix. All the patients 
provided written informed consent.
Randomization and Procedures
Eligible patients were randomly assigned, in a 1:1 
ratio, to undergo either TAVR with the SAPIEN 3 
system or surgical aortic-valve replacement with 
a commercially available bioprosthetic valve. Ran-
domization was conducted with the use of an 
electronic system, with block sizes of four, and 
was stratified according to site.
The SAPIEN 3 system and the procedures for 
TAVR and surgery have been described previ-
ously18; details are provided in Section D in the 
Supplementary Appendix. All TAVR procedures 
used the transfemoral access route. Balloon aortic 
valvuloplasty before and after TAVR was per-
formed at the operator’s discretion. Patients re-
ceived aspirin (81 mg) and clopidogrel (≥300 mg) 
before TAVR and were advised to continue taking 
these medications for at least 1 month after the 
procedure.
End Points
The primary end point was a composite of death 
from any cause, stroke, or rehospitalization at 
1 year after the procedure. All the patients un-
derwent neurologic examinations at baseline and 
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at 30 days. Patients who had suspected stroke after 
the procedure underwent serial neurologic exami-
nations, including assessment with the National 
Institutes of Health Stroke Scale and the modified 
Rankin scale at 90 days after the event. Rehos-
pitalization was defined as any hospitalization re-
lated to the procedure, the valve, or heart failure.
Key secondary end points were prespecified 
for hierarchical testing to control type 1 error. 
These included stroke, a composite of death or 
stroke, and new-onset atrial fibrillation at 30 days, 
as well as the length of the index hospitalization 
and a poor treatment outcome, which was a com-
posite of death or a low Kansas City Cardiomy-
opathy Questionnaire (KCCQ) overall summary 
score (with scores ranging from 0 to 100 and 
higher scores indicating fewer physical limitations 
and a greater feeling of well-being) at 30 days. 
Analyses of change in New York Heart Associa-
tion (NYHA) functional class, 6-minute walk-test 
distance, and KCCQ summary score were also 
performed. A list of all the secondary safety and 
effectiveness end points and their definitions are 
provided in Sections E and F in the Supplemen-
tary Appendix. All components of the primary end 
point and key secondary end points were adjudi-
cated by a clinical events committee whose mem-
bers were aware of the treatment assignments.
Statistical Analysis
We estimated that a sample of 864 patients would 
provide the trial with 90% power to show the non-
inferiority of TAVR to surgery with regard to the 
primary end point at 1 year, assuming a Kaplan–
Meier estimate of the rate of 14.6% in the TAVR 
group and 16.6% in the surgery group. A sample 
size of 1000 patients was chosen to allow for with-
drawals, crossovers, and loss to follow-up. To test 
for noninferiority, we determined whether the 
upper boundary of the 95% confidence interval 
for the difference in the rate of the primary end 
point between the TAVR group and the surgery 
group was less than the prespecified noninferi-
ority margin of 6 percentage points.
If the requirement for noninferiority was met, 
testing for the superiority of TAVR to surgery 
with regard to the primary end point was to be 
performed at a two-sided alpha level of 0.05. The 
primary analysis was performed in the as-treated 
population, which included patients who under-
went randomization and in whom the index pro-
cedure was initiated. Sensitivity analyses of the 
primary end point were performed in the inten-
tion-to-treat population, as well as with the use 
of multiple imputation to account for missing 
data (Section G in the Supplementary Appendix). 
An analysis of the hierarchical composite of death, 
stroke, or rehospitalization was performed with 
the use of the win ratio method.19 Prespecified 
subgroup analyses, with tests for interaction, were 
also performed.
There were two categories of secondary end 
points. For key secondary end points, testing for 
superiority was performed in a prespecified hierar-
chical order with the use of a gatekeeping method 
to control for multiple comparisons; P values are 
presented with claims of significance. For other 
secondary end points, analyses were performed 
without correction for multiple comparisons; haz-
ard ratios and 95% confidence intervals are pre-
sented without P values or claims of significance, 
and inferences drawn from these 95% confidence 
intervals may not be reproducible.
Continuous variables, which are presented as 
means with standard deviations or medians with 
interquartile ranges, were compared with the use 
of Student’s t-test or the Wilcoxon rank-sum test. 
Categorical and ordinal variables, which are pre-
sented as proportions, were compared with the 
use of Fisher’s exact test or the Wilcoxon rank-sum 
test. Continuous variables obtained after baseline 
were compared with the use of analysis of covar-
iance with adjustment for the baseline measure-
ment. Time-to-event analyses were performed with 
the use of Kaplan–Meier estimates and were com-
pared with the use of the log-rank test. Echocar-
diographic analyses were performed in the valve-
implant population, which included patients in 
whom the intended valve was implanted. All sta-
tistical analyses were performed with the use of 
SAS software, version 9.4 (SAS Institute).
R esult s
Patients
From March 2016 through October 2017, a total 
of 1000 patients were enrolled at 71 sites; 979 of 
the patients were from the United States, 8 from 
Canada, 7 from Australia or New Zealand, and 
6 from Japan. The patients were randomly as-
signed to undergo either TAVR (503 patients) or 
surgery (497 patients). The assigned procedure 
was performed in 950 patients (496 in the TAVR 
group and 454 in the surgery group), who com-
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posed the as-treated population, and the intended 
valve was implanted in 948. Among the patients 
who did not undergo the assigned procedure (7 in 
the TAVR group and 43 in the surgery group), the 
most common reason was withdrawal from the 
trial (in 41 patients), mainly owing to the decision 
not to undergo surgery or the preference to un-
dergo surgery at a nontrial site. Details regarding 
enrollment, randomization, and follow-up are pro-
vided in Figure S2 in the Supplementary Appendix.
Characteristics of the patients at baseline were 
balanced in the two groups (Table 1, and Fig. S3 
in the Supplementary Appendix), except for a 
higher percentage of patients with an NYHA 
class of III or IV in the TAVR group than in the 
surgery group (31.2% vs. 23.8%). The patients 
enrolled in this trial were younger (mean age, 73 
years), included more men (69.3%), and had lower 
STS-PROM scores (mean score, 1.9%) and fewer 
coexisting conditions than patients enrolled in 
previous randomized trials of TAVR.1-3 Baseline 
characteristics were similar in the as-treated popu-
lation and in patients who underwent randomiza-
tion and were not included in the as-treated popu-
lation (Table S1 in the Supplementary Appendix).
Procedural Outcomes
The median time from randomization to the in-
dex procedure was 11 days. One TAVR procedure 
was converted to surgery, and one surgical pro-
cedure was aborted. Concomitant procedures were 
performed in 7.9% of the patients in the TAVR 
group and in 26.4% of the patients in the sur-
gery group. Concomitant coronary revascular-
ization was performed in 6.5% and 12.8%, re-
spectively. In the TAVR group, conscious sedation 
was used in 65.1% of the patients. In the surgery 
group, minimally invasive surgery was performed 
in 24.3% of the patients, and the surgical valve 
was 23 mm in diameter or larger in 79.9%. De-
tails regarding the procedures are provided in 
Tables S2 and S3 and Figure S4 in the Supple-
mentary Appendix.
There were six deaths during the index hospi-
talization, which occurred in two patients in the 
TAVR group and in four patients in the surgery 
group. Other serious intraprocedural complica-
tions that occurred in the TAVR group included 
implantation of a second valve, annulus rupture, 
coronary-artery obstruction, and ventricular per-
foration (in one patient each) (Tables S4 and S5 
in the Supplementary Appendix).
Primary End Point
At 1 year, data regarding the primary end point 
were available for 98.4% of the patients. The 
composite of death from any cause, stroke, or 
rehospitalization had occurred in 42 patients 
(8.5%) in the TAVR group as compared with 68 
patients (15.1%) in the surgery group. The re-
quirements for both noninferiority and superior-
ity were met, with an absolute difference be-
tween the TAVR group and the surgery group of 
−6.6 percentage points (95% confidence interval 
[CI], −10.8 to −2.5; P<0.001 for noninferiority) 
and a hazard ratio of 0.54 (95% CI, 0.37 to 0.79; 
P = 0.001 for superiority) (Fig. 1A).
Results of an analysis performed with the use 
of the hierarchical win ratio method (win ratio, 
1.88; 95% CI, 1.29 to 2.76) were consistent with 
those of the primary analysis. Results of sensitiv-
ity analyses of the primary end point performed 
in the intention-to-treat population and with the 
use of multiple imputation for missing data were 
also consistent with those of the primary analy-
sis, as were results of analyses involving patients 
who underwent revascularization or other con-
comitant procedures and those who did not. Sub-
group analyses of the primary end point at 1 year 
showed no heterogeneity of treatment effect in 
any of the subgroups that were examined (Fig. 2). 
Details regarding these analyses are provided in 
Tables S6, S7, and S8 and Figure S5 in the Sup-
plementary Appendix.
Data regarding the individual components of 
the primary end point are shown in Figure 1B, 
1C, and 1D, and in Table S9 in the Supplemen-
tary Appendix. At 1 year, the Kaplan–Meier esti-
mate of the rate was 1.0% in the TAVR group as 
compared with 2.5% in the surgery group (hazard 
ratio, 0.41; 95% CI, 0.14 to 1.17) for death from 
any cause, 1.2% as compared with 3.1% (hazard 
ratio, 0.38; 95% CI, 0.15 to 1.00) for stroke, and 
7.3% as compared with 11.0% (hazard ratio, 
0.65; 95% CI, 0.42 to 1.00) for rehospitalization.
Secondary End Points
For key secondary end points, results of prespeci-
fied hierarchical testing are shown in Table 2. At 
30 days, TAVR resulted in a lower rate of stroke 
than surgery (0.6% vs. 2.4%; hazard ratio, 0.25; 
95% CI, 0.07 to 0.88; P = 0.02) and in lower rates 
of death or stroke (1.0% vs. 3.3%; hazard ratio, 
0.30; 95% CI, 0.11 to 0.83; P = 0.01) and new-
onset atrial fibrillation (5.0% vs. 39.5%; hazard 
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Characteristic
TAVR 
(N = 496)
Surgery 
(N = 454)
Age — yr 73.3±5.8 73.6±6.1
Male sex — no. (%) 335 (67.5) 323 (71.1)
Nonwhite race or ethnic group — no. (%)† 38 (7.7) 45 (9.9)
Body-mass index‡ 30.7±5.5 30.3±5.1
STS score§ 1.9±0.7 1.9±0.6
EuroSCORE II score¶ 1.5±1.2 1.5±0.9
NYHA class III or IV — no. (%) 155 (31.2) 108 (23.8)
Coronary artery disease — no./total no. (%) 137/494 (27.7) 127/454 (28.0)
Previous myocardial infarction — no./total no. (%) 28/495 (5.7) 26/452 (5.8)
Previous stroke — no./total no. (%) 17/496 (3.4) 23/453 (5.1)
Carotid disease — no./total no. (%) 61/481 (12.7) 50/442 (11.3)
Peripheral vascular disease — no./total no. (%) 34/494 (6.9) 33/453 (7.3)
COPD — no./total no. (%) 25/495 (5.1) 28/454 (6.2)
Creatinine >2 mg/dl — no. (%)‖ 1 (0.2) 1 (0.2)
Diabetes — no./total no. (%) 155/496 (31.2) 137/453 (30.2)
Atrial fibrillation — no./total no. (%) 78/496 (15.7) 85/453 (18.8)
Permanent pacemaker — no. (%) 12 (2.4) 13 (2.9)
Left bundle-branch block — no./total no. (%) 15/495 (3.0) 15/453 (3.3)
Right bundle-branch block — no./total no. (%) 51/495 (10.3) 62/453 (13.7)
Overall frailty — no./total no. (%)** 0/495 0/453
Pulmonary hypertension — no./total no. (%) 23/495 (4.6) 24/454 (5.3)
Aortic-valve area — cm2 0.8±0.2 0.8±0.2
Aortic-valve gradient — mm Hg 49.4±12.8 48.3±11.8
Left ventricular ejection fraction — % 65.7±9.0 66.2±8.6
Moderate or severe regurgitation — no./total no. (%)
Aortic 19/484 (3.9) 11/446 (2.5)
Mitral 6/477 (1.3) 14/437 (3.2)
Tricuspid 8/473 (1.7) 10/430 (2.3)
Systolic annular perimeter on CT — mm 78.1±6.9 78.6±7.2
Systolic annular area on CT — mm2 473.5±83.3 479.6±87.6
*  Plus–minus values are means ±SD. There were no significant between-group differences in baseline characteristics, 
except for New York Heart Association (NYHA) class III or IV (P<0.05). Data on aortic-valve area were available for 
459 patients in the TAVR group and 424 patients in the surgery group; aortic-valve gradient, 484 and 442, respective-
ly; left ventricular ejection fraction, 472 and 436; and systolic annular perimeter and area on computed tomography 
(CT), 486 and 441. COPD denotes chronic obstructive pulmonary disease, and TAVR transcatheter aortic-valve re-
placement.
†  Race or ethnic group was reported by the patient.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) scores range from 0 to 100%, with higher 
scores indicating a greater risk of death within 30 days after the procedure. STS-PROM uses an algorithm that is 
based on the presence of coexisting illnesses in order to predict 30-day operative mortality. The STS-PROM score 
equals the predicted mortality expressed as a percentage. Less than 5% of patients in the population on which the 
STS-PROM algorithm is based had a predicted operative mortality (score) of more than 10%.
¶  Scores on the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II range from 0 to 100, with high-
er scores indicating a greater risk of death within 30 days after the procedure.
‖  To convert the values for creatinine to micromoles per liter, multiply by 88.4.
**  Overall frailty was defined as the presence of three or more of the following criteria: grip strength of less than 18 kg, 
5-meter walk-test time of more than 6 seconds, serum albumin level of less than 3.5 g per deciliter, and Katz 
Activities of Daily Living total score of 4 or less (with scores ranging from 0 to 6 and higher scores indicating greater 
independence in performing activities of daily living).
Table 1. Characteristics of the Patients at Baseline.*
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ratio, 0.10; 95% CI, 0.06 to 0.16; P<0.001). TAVR 
also resulted in a shorter index hospitalization 
than surgery (3 days vs. 7 days, P<0.001) and in 
a lower risk of a poor treatment outcome (death 
or a low KCCQ score) at 30 days (3.9% vs. 30.6%, 
P<0.001), a result that was confirmed with the 
use of multiple imputation for missing data 
(Table S10 in the Supplementary Appendix). At 1 
year, the rate of death or disabling stroke was 
1.0% in the TAVR group as compared with 2.9% 
in the surgery group (hazard ratio, 0.34; 95% CI, 
0.12 to 0.97).
Complete data regarding secondary end 
points at 30 days and 1 year are provided in Ta-
bles S9 and S11 through S16 and Figures S6 
through S9 in the Supplementary Appendix. The 
percentage of patients who were discharged to 
home or self-care was 95.8% in the TAVR group 
as compared with 73.1% in the surgery group. 
There were no significant differences between 
the two groups with regard to most safety end 
points at 30 days, including major vascular com-
plications and new permanent pacemaker inser-
tions. The percentage of patients with new left 
Figure 1. Time-to-Event Curves for the Primary Composite End Point and the Individual Components of the Primary End Point.
Shown are Kaplan–Meier estimates of the rate of the primary composite end point (Panel A) and the individual components of the pri-
mary end point, which are death from any cause (Panel B), stroke (Panel C), and rehospitalization (Panel D), in patients who underwent 
transcatheter aortic-valve replacement (TAVR) and those who underwent surgical aortic-valve replacement. The insets show the same 
data on an enlarged y axis.
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bundle-branch block at 1 year was 23.7% in the 
TAVR group as compared with 8.0% in the sur-
gery group (hazard ratio, 3.43; 95% CI, 2.32 to 
5.08). The percentage of patients with life-threat-
ening or major bleeding was 3.6% in the TAVR 
group as compared with 24.5% in the surgery 
group (hazard ratio, 0.12; 95% CI, 0.07 to 0.21). 
Changes from baseline in the NYHA class, 6-min-
ute walk-test distance, and KCCQ score at 30 days 
and 1 year are shown in Figure 3.
Echocardiographic Findings
At 30 days, the mean aortic-valve gradient was 
12.8 mm Hg in the TAVR group and 11.2 mm 
Hg in the surgery group. The mean aortic-valve 
area was 1.7 cm2 and 1.8 cm2, respectively. The 
percentage of patients with moderate or severe 
paravalvular regurgitation did not differ signifi-
cantly between the TAVR group and the surgery 
group (0.8% and none, respectively, at 30 days; 
0.6% and 0.5% at 1 year). The percentage of 
patients with mild paravalvular regurgitation at 
1 year was higher with TAVR than with surgery 
(29.4% vs. 2.1%). There were no episodes of valve 
thrombosis associated with clinical events. Six 
asymptomatic patients (five in the TAVR group 
and one in the surgery group) had findings sug-
gestive of valve thrombosis, including increased 
valve gradients and evidence on imaging of re-
stricted leaflet motion. Details regarding echo-
cardiographic findings are provided in Tables 
S17 and S18 and Figures S10 through S13 in the 
Supplementary Appendix.
Discussion
There are three main findings of the PARTNER 
3 trial. First, TAVR, performed by means of 
transfemoral placement of the balloon-expand-
able SAPIEN 3 system, was superior to surgery 
Figure 2. Subgroup Analyses of the Primary Composite End Point of Death from Any Cause, Stroke, or Rehospitalization.
All percentages are Kaplan–Meier estimates. Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) scores range from  
0 to 100%, with higher scores indicating a greater risk of death within 30 days after the procedure. Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ) overall summary scores range from 0 to 100, with higher scores indicating fewer physical limitations and a greater 
 feeling of well-being. NYHA denotes New York Heart Association.
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with regard to the primary composite end point 
of death, stroke, or rehospitalization at 1 year. 
Multiple sensitivity analyses confirmed the ro-
bustness of the results of the primary analysis. 
Results for the three components of the primary 
end point favored TAVR at both 30 days and 1 year. 
Second, analyses of key secondary end points, 
which were adjusted for multiple comparisons, 
showed that TAVR was associated with a sig-
nificantly lower rate of new-onset atrial fibrilla-
tion at 30 days, a shorter index hospitalization, 
and a lower risk of a poor treatment outcome 
(death or a low KCCQ score) at 30 days than sur-
gery. Third, patients who underwent TAVR had 
more rapid improvements in the NYHA class, 
6-minute walk-test distance, and KCCQ score 
than those who underwent surgery.
During the past decade, recommendations for 
TAVR in patients with severe, symptomatic aor-
tic stenosis have been expanded to include strata 
with incrementally lower surgical risk.12,13,20,21 
Current clinical practice has restricted the use of 
TAVR in patients who are at low risk and in 
younger patients, for whom surgery is standard 
therapy. Previous research that supports the use 
of TAVR in low-risk patients is limited, mostly 
consisting of retrospective, observational stud-
ies.22-27 One randomized trial of TAVR with an 
early-generation self-expanding valve in 280 pa-
tients at all risk levels (>80% with an STS-PROM 
score of <4%) showed that TAVR was noninferior 
to surgery with more than 5 years of follow-up.16 
A recent prospective series of TAVR with balloon-
expandable and self-expanding valves in 200 low-
risk patients without frailty from 11 U.S. centers 
showed no deaths or disabling strokes at 30 days.17
In the PARTNER 3 trial, surgical outcomes 
were excellent: in the surgery group, the rate of 
death at 30 days was 1.1%, and the rate of a 
composite of death or disabling stroke at 1 year 
was 2.9%. Nevertheless, in the TAVR group, the 
rate of death at 30 days was even lower (0.4%), 
and the rate of death or disabling stroke at 1 year 
was only 1.0%. Complications that were more 
frequent with TAVR than with surgery in previ-
ous trials1-3,6,28-32 occurred with similar frequency 
in the two groups in this trial, including major 
vascular complications, new permanent pace-
maker insertions, moderate or severe paravalvu-
lar regurgitation, and coronary-artery obstruction. 
Life-threatening or major bleeding occurred less 
frequently with TAVR than with surgery. Results 
for other secondary end points, including new 
left bundle-branch block and mild paravalvular 
regurgitation, favored surgery. Between-group dif-
ferences in transvalvular aortic-valve gradients 
End Point
TAVR 
(N = 496)
Surgery 
(N = 454)
TAVR vs. Surgery 
(95% CI)† P Value‡
New-onset atrial fibrillation at 30 days — no./total no. (%)§¶ 21/417 (5.0) 145/369 (39.5) 0.10 (0.06 to 0.16) <0.001
Length of index hospitalization — median no. of days (inter-
quartile range)
3.0 (2.0 to 3.0) 7.0 (6.0 to 8.0) −4.0 (−4.0 to −3.0) <0.001
Death from any cause, stroke, or rehospitalization at 1 year — 
no. (%)§
42 (8.5) 68 (15.1) 0.54 (0.37 to 0.79) 0.001
Death, KCCQ score of <45, or decrease from baseline in KCCQ 
score of ≥10 points at 30 days — no./total no. (%)‖
19/492 (3.9) 133/435 (30.6) −26.7 (−31.4 to −22.1) <0.001
Death or stroke at 30 days — no. (%)§ 5 (1.0) 15 (3.3) 0.30 (0.11 to 0.83) 0.01
Stroke at 30 days — no. (%)§ 3 (0.6) 11 (2.4) 0.25 (0.07 to 0.88) 0.02
*  Key secondary end points were tested in a prespecified hierarchical order with the use of a gatekeeping method to control for multiple com-
parisons.
†  For the first, third, fifth, and sixth end points, the value is a hazard ratio. For the second end point, the value is a difference in medians esti-
mated with the use of bootstrap techniques. For the fourth end point, the value is a difference in proportions and is presented in percentage 
points.
‡  For the first, third, fifth, and sixth end points, the P value was based on the log-rank test. For the second end point, the P value was based 
on the Wilcoxon rank-sum test. For the fourth end point, the P value was based on Fisher’s exact test.
§  The percentages are Kaplan–Meier estimates.
¶  Patients who had atrial fibrillation before the procedure were excluded from the analysis.
‖  Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary scores range from 0 to 100, with higher scores indicating fewer physi-
cal limitations and a greater feeling of well-being.
Table 2. Key Secondary End Points.*
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also favored surgery, although this was not the 
case in previous randomized trials of TAVR2,3,5; 
this result was probably due to the greater use of 
larger surgical valves in this trial.
The most important limitation of this trial is 
that our current results reflect only 1-year out-
comes and do not address the problem of long-
term structural valve deterioration.33,34 Definitive 
conclusions regarding the advantages and disad-
vantages of TAVR as compared with surgery (with 
either bioprosthetic or mechanical valves) depend 
on long-term follow-up. In this trial involving 
younger, low-risk patients, the protocol requires 
clinical and echocardiographic follow-up to con-
tinue for at least 10 years.
This trial has several other limitations. First, 
in this trial, as in previous TAVR trials, adjudica-
tion of end points was not blinded, which could 
have resulted in bias in outcome assessment. 
Second, the results apply only to the defined 
trial population, which excluded patients with 
poor transfemoral access, bicuspid aortic valves, 
or other anatomical or clinical factors that in-
creased the risk of complications associated with 
either TAVR or surgery. Third, the findings can-
not be extrapolated to TAVR performed with 
other systems or by less experienced operators.35,36
Fourth, more patients in the surgery group than 
in the TAVR group withdrew from the trial (both 
early and late). Fifth, missing data regarding 
NYHA class, 6-minute walk-test distance, KCCQ 
score, and follow-up echocardiograms were not 
fully accounted for with multiple imputation. 
Sixth, this analysis did not examine the rate and 
relevance of asymptomatic valve thrombosis.37,38
This issue is being examined in a randomized 
subtrial, in which 435 patients are undergoing 
serial computed tomographic angiography for the 
detection of abnormalities in valve-leaflet function, 
with investigators unaware of imaging findings.
The proof-of-concept first case of TAVR per-
formed by Cribier and colleagues in 200239 was 
intended to open a treatment pathway for the 
highest-risk patients with limited therapeutic op-
tions. Our findings in low-risk patients suggest 
that the value of TAVR as compared with surgery 
may be independent of risk profiles.
In conclusion, among patients with severe 
aortic stenosis who were at low risk for death 
with surgery, the rate of the composite of death, 
stroke, or rehospitalization at 1 year was signifi-
cantly lower with TAVR than with surgical aortic-
valve replacement.
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